Candel Therapeutics is preparing a U.S. approval push for its prostate cancer drug later this year, backed by a $100 million financing deal from RTW Investments to fund the launch.
Longevity News
As Candel Therapeutics gears up for a planned U.S.
Source: FierceBiotech - All • Published: 20 Feb 2026, 11:32
Continue exploring
Related longevity signals
Longevity TechnologyNRG Therapeutics shows promising lab results for new ALS drug candidateNRG Therapeutics’ preclinical report invites readers to examine lab and mechanistic data for a novel ALS drug candidate and its next-stage plans.PR NewswireCARsgen Therapeutics Announces 2026 Interim ResultsReport on a CAR T developer's 2026 interim results covering commercial progress, regulatory milestones, and clinical updates for multiple CAR T programs.Nature - BiotechnologyMRNA-LNP therapeutics for obesity: weight loss with metabolic repairMRNA-LNP approaches that program tissues to produce therapeutic proteins for obesity, outlining advances in delivery strategies and therapeutic potential.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.